Open AccessNovel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody
Author(s) -
Zhu Di,
Wang Zheng,
Xu Yunxia,
Lin Jing,
Qiu Mei,
Liu Jianghai,
Li Xinlei
Publication year - 2022
Publication title -
engineering in life sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.547
H-Index - 57
eISSN - 1618-2863
pISSN - 1618-0240
DOI - 10.1002/elsc.202200028
Subject(s) - monoclonal antibody , chinese hamster ovary cell , antibody , biopharmaceutical , green fluorescent protein , microbiology and biotechnology , cell sorting , single domain antibody , cell culture , phage display , chemistry , biology , flow cytometry , biochemistry , immunology , gene , genetics
Abstract Animal‐derived anti‐IgG secondary antibodies are currently employed to stain and screen of human monoclonal antibody(mAb)‐producing cells, but using animal‐derived antibodies may raise the concerns of high cost, complicated operations and biological safety issues in biopharmaceutical manufacturing. Nanobodies(VHHs) are attractive forms of antibodies for their straightforward engineering and expression in both eukaryotic and prokaryotic systems. Using phage‐displayed immune llama VHH library, we identified new anti‐Fc VHHs that could bind to human Fc with high affinity. In GFP fusion format, the anti‐Fc VHH‐GFP generated dramatically stronger FACS signals than AF488 conjugated anti‐IgG antibodies when used for staining mAb‐producing CHO cells. Furthermore, preparative sorting of CHO cells based on anti‐Fc VHH‐GFP staining resulted in the enrichment of cell lines capable of synthesizing mAb at high productivity. This safe and cost‐efficient anti‐Fc VHH‐GFP may optimize the process of generating highly productive cell lines for therapeutic mAb production compared to conventional animal‐derived fluorescent antibodies.